PG-116800

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NamePG-116800
Drug Alias NamePG-530742PG-116800PGE-7113313
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 9 inhibitorsMatrix metalloproteinase 3 inhibitorsMatrix metalloproteinase-2 inhibitors +[5] 
TargetsMatrix metalloproteinase 9Matrix metalloproteinase 3Matrix metalloproteinase 13 +[5] 
Therapy Area/IndicationsMyocardial InfarctionHeart FailureCardiomegaly +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProcter & Gamble Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProcter & Gamble Company
Active IndicationsN/A
Inactive IndicationsMyocardial InfarctionHeart FailureCardiomegaly +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank